Revelation Biosciences, Inc.
REVB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001810560
No open-market purchases or sales by Revelation Biosciences, Inc. insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $313.2K in total; no superinvestor holds it.
Other share classesREVBW
Q1 2025 vs. Q4 2024
How the institutions holding Revelation Biosciences, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 10 | 7 | −3 |
| Shares | 107.2K | 8.54K | −98.7K (−92.0%) |
| Value | $49.4K | $13.3K | −$36.1K (−73.0%) |
New holders (3)
Institutions that held Revelation Biosciences, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| IFP Advisors, Inc | 4,250 | $1.61K | 0.00% |
| UBS Group AG | 349 | $918 | 0.00% |
| Danske Bank A/S | 1 | $3 | 0.00% |
Sold out (6)
Institutions that held Revelation Biosciences, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| XTX Topco Ltd | 49,840 | $23.0K |
| Two Sigma Securities, LLC | 29,102 | $13.4K |
| StoneX Group Inc. | 14,137 | $6.52K |
| Geode Capital Management, LLC | 10,964 | $5.05K |
| Morgan Stanley | 6 | $3 |
| POM Investment Strategies, LLC | 1 | $0 |